Tobias Hess has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Evaluation of Glidants for Enhancing the Flowability of Poorly Flowing Powdered Materials with Varying Particle Sizes and Morphologies

    by Daniel Zakowiecki, Peter Edinger, Michael Wagner, Tobias Hess, Dariusz Lipiak, Krzysztof Cal

    Background: An increasing number of commercially available drug substances and bioactive ingredients are characterized by poor flowability. Inadequate flow properties may lead to material blockage during transport within production lines, as well as the formation of air voids within the bulk. Such phenomena can disrupt the technological process and may even result in batches that fail to meet quality requirements. Therefore, ensuring adequate powder flow is of utmost importance in the manufacture of health-related products. Methods: Binary mixtures were prepared using one of four model substances (ibuprofen, metamizole sodium, mefenamic acid, or sunflower lecithin) combined with a glidant (colloidal silica, precipitated silica, or tricalcium phosphate). The glidant content ranged from 0.5 to 10.0% w/w depending on the model substance, and mixing was carried out for 5–30 min. The resulting binary mixtures were evaluated for flow properties using the angle of repose method, and in selected cases, bulk density was also determined. Results/Conclusions: The study demonstrated that powder flow improvement depended not only on the glidant but primarily on the properties of the host material (particle size, shape, and bulk density). Coarser powders such as ibuprofen responded well to low glidant levels, although excessive silicon dioxide caused oversilication. Metamizole sodium showed progressively better flow with increasing particle size and density, and tribasic calcium phosphate further improved performance, particularly with longer mixing times. Very fine or cohesive powders, such as mefenamic acid and sunflower lecithin, showed limited response to silica-based glidants, whereas tribasic calcium phosphate proved more effective and additionally increased bulk density. Overall, no universal glidant strategy was identified; effective flow enhancement requires a tailored approach based on specific powder characteristics.


  • Open Access

    Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

    by Daniel Zakowiecki, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Daria Myslitska, Michal Smolenski, Justyna Dobosz, et al.

    Background/Objectives: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media, posing a significant formulation challenge. Methods: To address this, phosphate-based excipients were employed to prepare both traditional single-unit dosage forms (tablets) and modern multiple-unit pellet systems (MUPS). These formulations were successfully developed and thoroughly evaluated for their physical properties and performance. Results: The resulting formulations demonstrated very good mechanical strength, including appropriate hardness and friability, alongside strong chemical stability. Their dissolution profiles met the requirements of the compendial monograph for Rivaroxaban Tablets and were comparable to those of the reference product, Xarelto® film-coated tablets. Conclusions: This study shows the potential for producing effective, stable, and patient-friendly medications that meet the needs of contemporary society, where an increasing number of individuals suffer from lactose intolerance or seek vegan-friendly alternatives.


  • Open Access

    Effect of Compaction Pressure on the Enzymatic Activity of Pancreatin in Directly Compressible Formulations

    by Daniel Zakowiecki, Peter Edinger, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Svitlana Romanova, Grzegorz Garbacz

    Tableting of biomolecules is a challenging formulation phase due to their sensitivity to various process parameters, such as compression pressure, process dynamics, or the temperature generated. In the present study, pancreatin was employed as a model enzyme mixture, which was formulated in tablet form utilizing the synergistic effects of brittle and plastic excipients (dibasic calcium phosphate and microcrystalline cellulose, respectively). The effect of varying compaction pressure and lubricant concentration on the generated temperature and enzymatic activity was evaluated. The tablets were analyzed for pancreatin content and the activity of two enzymes (protease and amylase) using pharmacopoeial tests. This study indicated that the formulations proposed here allow tableting over a wide range of compaction pressures without adversely affecting pancreatin content and its enzymatic activity.


  • Open Access

    Towards the Continuous Manufacturing of Liquisolid Tablets Containing Simethicone and Loperamide Hydrochloride with the Use of a Twin-Screw Granulator

    by Daniel Zakowiecki, Margarethe Richter, Ceren Yuece, Annika Voelp, Maximilian Ries, Markos Papaioannou, Peter Edinger, Tobias Hess, Krystyna Mojsiewicz-Pieńkowska, Krzysztof Cal

    Continuous manufacturing is becoming the new technological standard in the pharmaceutical industry. In this work, a twin-screw processor was employed for the continuous production of liquisolid tablets containing either simethicone or a combination of simethicone with loperamide hydrochloride. Both active ingredients present major technological challenges, as simethicone is a liquid, oily substance, and loperamide hydrochloride was used in a very small amount (0.27% w/w). Despite these difficulties, the use of porous tribasic calcium phosphate as a carrier and the adjustment of the settings of the twin-screw processor enabled the optimization of the characteristics of the liquid-loaded powders and made it possible to efficiently produce liquisolid tablets with advantages in physical and functional properties. The application of chemical imaging by means of Raman spectroscopy allowed for the visualization of differences in the distribution of individual components of the formulations. This proved to be a very effective tool for identifying the optimum technology to produce a drug product.


  • Open Access

    The Use of Calcium Phosphate-Based Starter Pellets for the Preparation of Sprinkle IR MUPS Formulation of Rosuvastatin Calcium

    by Krzysztof Cal, Barbara Mikolaszek, Tobias Hess, Markos Papaioannou, Joanna Lenik, Patrycja Ciosek-Skibińska, Helene Wall, Jadwiga Paszkowska, Svitlana Romanova, Grzegorz Garbacz, et al.

    Sprinkle formulations represent an interesting concept of medicinal products aimed at the steadily growing population of patients suffering from swallowing difficulties (dysphagia). In the present work, immediate-release sprinkle MUPS (multiple-unit pellet system) containing rosuvastatin calcium as a model drug substance was successfully developed. The formulation was prepared by drug layering technique using novel calcium phosphate-based starting pellets (PharSQ® Spheres CM) of three different particle sizes. The study showed that the developed multiparticulates were characterized by uniform distribution of coating layers thickness, as well as fast dissolution rate (more than 85% of rosuvastatin calcium dissolved within 30 min, as required by the relevant USP/NF monograph). Rosuvastatin calcium, like other statins, has a bitter, unpleasant taste. Investigations conducted with an electronic tongue suggested that the developed formulation achieved the desired taste-masking efficiency. The effect was found to be particle size-dependent, improving as the size of the multiparticulates increased.


  • Open Access

    Development of a Biphasic-Release Multiple-Unit Pellet System with Diclofenac Sodium Using Novel Calcium Phosphate-Based Starter Pellets

    by Daniel Zakowiecki, Maja Frankiewicz, Tobias Hess, Krzysztof Cal, Maciej Gajda, Justyna Dabrowska, Bartlomiej Kubiak, Jadwiga Paszkowska, Marcela Wiater, Dagmara Hoc, et al.

    Novel calcium phosphate-based starter pellets were used to develop a biphasic-release multiple-unit pellet system (MUPS) with diclofenac sodium as a model drug in the form of hard gelatin capsules. For comparative purposes, corresponding formulations based on the inert cores made of microcrystalline cellulose, sucrose and isomalt were prepared. The developed system consisted of two types of drug-layered pellets attaining different release patterns: delayed-release (enteric-coated) and extended-release. Dissolution characteristics were examined using both compendial and biorelevant methods, which reflected fed and fasting conditions. The results were collated with an equivalent commercial product but prepared with the direct pelletization technique.